WEBSITE BSE:0 NSE: Inc. Year: 2014 Industry: Hospital & Healthcare Services My Bucket: Add Stock
Last updated: 15:42
No Notes Added Yet
Incorporated in 2014, Nephro Care India Limited operate as a comprehensive treatment center in Kolkata. Specialized in nephrology care along with offering clinical and lifestyle solutions to patients. With an army of expert doctors and experienced paramedical professionals along with a skilled management team, Nephro Care provides renal insufficiency treatment and chronic kidney disease management. Their state-of-the-art facilities and experienced team ensure high-quality care with an aim to improve patients' quality of life. Their mission emph...Read More
Incorporated in 2014, Nephro Care India Limited operate as a comprehensive treatment center in Kolkata. Specialized in nephrology care along with offering clinical and lifestyle solutions to patients. With an army of expert doctors and experienced paramedical professionals along with a skilled management team, Nephro Care provides renal insufficiency treatment and chronic kidney disease management. Their state-of-the-art facilities and experienced team ensure high-quality care with an aim to improve patients' quality of life. Their mission emphasizes compassionate care and patient education to manage and prevent disease progression.Nephro care also focus on equity release schemes, lifetime mortgages, and retirement interest-only mortgages for individuals aged 55 and above. It's holistic approach ensures patients receive support not only for physical health but also for mental and emotional well-being. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹131 Cr.
Stock P/E 36.1
P/B 2.4
Current Price ₹79.8
Book Value ₹ 32.7
Face Value 10
52W High ₹183
Dividend Yield 0%
52W Low ₹ 50.1
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Dec 2025 |
|---|---|
| Net Sales | 23 |
| Other Income | 0 |
| Total Income | 23 |
| Total Expenditure | 21 |
| Operating Profit | 2 |
| Interest | 0 |
| Depreciation | 1 |
| Exceptional Income / Expenses | 0 |
| Profit Before Tax | 1 |
| Provision for Tax | 0 |
| Profit After Tax | 0 |
| Adjustments | 0 |
| Profit After Adjustments | 0 |
| Adjusted Earnings Per Share | 0.3 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 2 | 3 | 17 | 27 | 46 | 23 |
| Other Income | 0 | 0 | 0 | 0 | 2 | 0 |
| Total Income | 2 | 3 | 17 | 28 | 48 | 23 |
| Total Expenditure | 2 | 3 | 14 | 21 | 40 | 21 |
| Operating Profit | 0 | 0 | 3 | 7 | 7 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 1 | 2 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 3 | 6 | 5 | 1 |
| Provision for Tax | 0 | 0 | 0 | 2 | 1 | 0 |
| Profit After Tax | 0 | -0 | 2 | 5 | 4 | 0 |
| Adjustments | 0 | 0 | 0 | -0 | 0 | 0 |
| Profit After Adjustments | 0 | -0 | 2 | 4 | 4 | 0 |
| Adjusted Earnings Per Share | 4.4 | -0 | 2.4 | 3.8 | 2.2 | 0.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 70% | 148% | 0% | 0% |
| Operating Profit CAGR | 0% | 0% | 0% | 0% |
| PAT CAGR | -20% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -42% | NA% | NA% | NA% |
| ROE Average | 11% | 73% | 161% | 161% |
| ROCE Average | 14% | 48% | 33% | 33% |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Shareholder's Funds | 0 | 0 | 3 | 15 | 53 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 1 | 2 | 2 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | -0 | -0 | 1 |
| Total Current Liabilities | 0 | 2 | 3 | 6 | 14 |
| Total Liabilities | 1 | 5 | 8 | 21 | 68 |
| Fixed Assets | 0 | 1 | 3 | 5 | 31 |
| Other Non-Current Assets | 1 | 2 | 2 | 5 | 9 |
| Total Current Assets | 1 | 1 | 3 | 11 | 28 |
| Total Assets | 1 | 5 | 8 | 21 | 68 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 1 | 2 | 1 |
| Cash Flow from Operating Activities | 0 | 1 | 4 | 1 | 8 |
| Cash Flow from Investing Activities | -0 | -3 | -2 | -8 | -40 |
| Cash Flow from Financing Activities | 0 | 2 | -0 | 6 | 35 |
| Net Cash Inflow / Outflow | 0 | 0 | 2 | -1 | 3 |
| Closing Cash & Cash Equivalent | 0 | 1 | 2 | 1 | 5 |
| # | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 4.44 | -0.01 | 2.37 | 3.78 | 2.21 |
| CEPS(Rs) | 5.09 | 0.1 | 3.16 | 4.23 | 3.7 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 0.75 | 0.5 | 2.53 | 12.62 | 32.44 |
| Core EBITDA Margin(%) | 8.47 | 3.67 | 20.04 | 23.75 | 12.76 |
| EBIT Margin(%) | 8.19 | 0.49 | 15.46 | 23.17 | 10.73 |
| Pre Tax Margin(%) | 6.46 | 0.01 | 15.08 | 22.85 | 10.49 |
| PAT Margin (%) | 4.86 | -0.29 | 13.88 | 16.53 | 7.91 |
| Cash Profit Margin (%) | 5.57 | 2.97 | 18.47 | 18.47 | 13.25 |
| ROA(%) | 7.88 | -0.34 | 37.08 | 31 | 8.16 |
| ROE(%) | 591.33 | -3.84 | 156.92 | 51.3 | 10.62 |
| ROCE(%) | 21.11 | 0.9 | 65.72 | 62.97 | 14.42 |
| Receivable days | 0 | 20.54 | 2.52 | 1.32 | 13.4 |
| Inventory Days | 5.04 | 10.44 | 6.99 | 5.61 | 6.26 |
| Payable days | 94.24 | 96.02 | 51.44 | 56.5 | 79.79 |
| PER(x) | 0 | 0 | 0 | 0 | 57.61 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 3.92 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.12 | 0.71 | 0.04 | 0.39 | 4.45 |
| EV/Core EBITDA(x) | 1.36 | 18.94 | 0.19 | 1.55 | 27.7 |
| Net Sales Growth(%) | 0 | 87.66 | 399.14 | 59.31 | 69.04 |
| EBIT Growth(%) | 0 | -88.76 | 0 | 138.7 | -21.7 |
| PAT Growth(%) | 0 | -111.05 | 0 | 89.77 | -19.18 |
| EPS Growth(%) | 0 | -100.22 | 0 | 59.44 | -41.65 |
| Debt/Equity(x) | 46.18 | 5.12 | 0.98 | 0 | 0 |
| Current Ratio(x) | 1.08 | 0.66 | 0.89 | 1.86 | 2.01 |
| Quick Ratio(x) | 1.03 | 0.55 | 0.75 | 1.8 | 1.93 |
| Interest Cover(x) | 4.74 | 1.01 | 40.23 | 74.13 | 44.86 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 |
| # | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Promoter | 61.38 | 61.38 | 61.44 | 61.47 | 61.71 |
| FII | 3.92 | 4.06 | 3.5 | 3.47 | 0.73 |
| DII | 4.82 | 3.41 | 2.24 | 1.04 | 1.3 |
| Public | 29.87 | 31.14 | 32.82 | 34.02 | 36.27 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Promoter | 1.01 | 1.01 | 1.01 | 1.01 | 1.02 |
| FII | 0.06 | 0.07 | 0.06 | 0.06 | 0.01 |
| DII | 0.08 | 0.06 | 0.04 | 0.02 | 0.02 |
| Public | 0.49 | 0.51 | 0.54 | 0.56 | 0.6 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Total | 1.65 | 1.65 | 1.65 | 1.65 | 1.65 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
